When combined with gefitinib, a small-molecule EGFR inhibitor, TAK-701 effectively suppresses the phosphorylation of both c-MET and EGFR, along with their downstream signaling pathways, in HCC827-HGF tumor cells. This evidence concerns the gene MET and neoplasm.